Cheelcare's Companion Bookings Soar 147% YoY in Record Second Consecutive Month
summarizeSummary
Cheelcare Inc. reported record monthly bookings for its Companion power assist product line for April 2026, marking the second consecutive month of record performance. April bookings surged 147% year-over-year and 38.5% sequentially. This significant commercial momentum follows the company's achievement of U.S. Medicare and Medicaid reimbursement eligibility for the Companion platform in January 2026, which has expanded insurance-funded access. Management also noted a substantial increase in Request for Quotations (RFQs), up 64% sequentially in April, which they view as a leading indicator of future demand. These strong booking figures and increasing RFQs suggest a significant acceleration in commercial activity and potential for substantial future revenue growth, indicating the company may be entering a new growth phase. Traders should monitor the conversion of these bookings into recognized revenue and continued growth in RFQs and future booking reports.
At the time of this announcement, CHCRF was trading at $0.66 on OTC in the Life Sciences sector. The 52-week trading range was $0.66 to $0.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.